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the relevant clinical criteria. Individual Cancer Drug Fund requests (ICDFRs) can also 
be made for patients outside of routine cohort CDF criteria for rare diseases or, in 
cases where a decision has been made not to fund a cohort, for patients for whom 
clinical exceptionality from this cohort can be demonstrated. ICDFRs are screened to 
ensure that the request is appropriate and are then appraised by one of four regional 
CDF panels. This research aimed to evaluate whether access to oncologics through 
ICDFRs varies by region. Methods: ICDFR outcomes data (April 2013–March 2014) 
was extracted from the NHS website and stratified by NHS estimates of the resident 
population by region. All statistical analyses were performed using a Chi-squared 
test. Results: 1029 ICDFR applications were received for consideration (London, 
301; East and Midlands, 231; North England, 181; South England, 316), 46% of which 
were deemed ineligible by screening, significantly varying by region (p< 0.0001, 
range 22% (North England) to 67% (East and Midlands)). 50% of screened ICDFRs 
were approved, which varied substantially by region (p< 0.0001, range 37% (East and 
Midlands) to 72% (South England)). Overall, around 5.5 ICDFRs were accepted per 
million patients across England, however, between regions this ratio varied over 
six-fold (range 1.9 (East and Midlands) to 12.0 (South England)). ConClusions: The 
notable variations in ICDFR screening, acceptance, and population level approval 
rates, which are larger than what we may expect based on regional variations in case 
mix, suggest that regional areas must further collaborate to ensure that patients 
have equitable access to the Cancer Drugs Fund.
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objeCtives: Oncology drugs in England rejected or not yet assessed by the National 
Institute for Health and Care Excellence (NICE) can seek funding through the Cancer 
Drug Fund (CDF). Each drug is given a score via the national CDF Prioritisation Tool 
which is a clinically-led process where cost-effectiveness is considered only as a 
tie-breaker. The objective of this research was to determine which score secures CDF 
approval and how the decision is related to the Incremental Cost Effectiveness Ratio 
(ICER). Methods: CDF drug reports (including the scores) published from April 
2013 until March 2014 were analysed and mapped to the national May CDF list. Each 
score comprises of a number indicating the clinical profile of the drug and the letter 
(A-D, U) representing the strength of evidence. The ICER per indication was sourced 
from NICE assessments and the relationship to the CDF list was analysed. Results: 
A review of 56 CDF reports showed that generally, drugs with scores below 1B (posi-
tive clinical profile, one Phase III published study) were not granted CDF funding. 
Positive decisions were made for 19 indications with scores ranging from 1B to 8B. 
The most common reasons for not approving drugs with a score of ≥ 1B were the 
trial not representing the NHS England population; lack of clinical effectiveness or 
questionable wider clinical support. The ICERs does not appear to have an influence 
on the CDF decision as ICERs for both CDF and non-CDF drugs ranged from £30,000 
to £150,000. ConClusions: The result of this research confirms that the clinical 
profile and the level of evidence are the most important factors for the CDF inclusion 
while cost-effectiveness is not a standard part of the decision-making process. The 
findings can also support manufacturers in estimating the likely outcome of the 
CDF application based on the pre-calculated score.
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objeCtives: The Russian pharmaceutical market is one of the fastest growing in the 
world. Its value is predicted to rise from $24 billion in 2013 to $75 billion by 2020(1). 
For industry the market opportunity is compelling, however market access across 
this vast region is complex and challenging, specifically for high-cost products. This 
research was conducted to have a closer look at the Russian pharmaceutical pricing 
and reimbursement model, and further explore access barriers. Methods: The 
research was conducted through in-depth secondary research and interviews with 
stakeholders in Russia including members of the Russian ministry of health, Federal 
health insurance fund, and regional/municipal health authorities. Results: At the 
federal level, the Ministry of Health and Social Development (MoHSD) develops 
strategy, policy and budgets in health care. The MoHSD has developed an Essential 
Drugs List (EDL) to ensure that drugs are made available at a harmonized price 
across Russia. However being listed on the EDL does not ensure reimbursement. In 
Russia, regional health authorities function as independent units. Drug provision 
and systems of reimbursement are usually developed at a regional level. However, 
each of the 82 Russian regions also has fundamentally different demographic and 
economic conditions, creating unique requirements and subsequent disparity in 
health care delivery and funding across the regions. It is critical for manufacturers 
to get their product listed in individual regional formularies, which will be used 
as the foundation for the reimbursement systems as they are rolled out in the 
future. ConClusions: The Russian market is vast, fast growing and clearly offers 
massive opportunities for pharmaceutical companies. However, this is a complex 
market, with a considerable regional variation in decision making. Industry will 
have to invest in gaining regional insight to determine priority regions and justify 
market access plans according to the dynamics of a specific region.
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performed to assess evolution of HRU and medical costs over time. Similar analysis 
was conducted for Medicare-eligible patients. Results: Of the 3,940 commercially-
insured and 1,658 Medicare-eligible individuals with NETs, 63.0% (n= 2,484) and 
67.0% (n= 1,111) were untreated, respectively. Among untreated commercially-
insured individuals with NETs, carcinoid syndrome (20.9%), nausea/vomiting (14.2%) 
and liver metastasis (11.6%) were the most prevalent symptoms/co-morbidities in 
the 12-month post-index period; 37.7 % had hospitalization admissions and 31.4% 
had emergency department (ED) visits, and the mean annual number of physician 
office visits was 18.7. The total monthly medical cost increased from $3,028 in the 
pre-index period to $4,159 in the post-index period. Among untreated Medicare-
eligible individuals with NETs, carcinoid syndrome (14.3%), nausea/vomiting (12.5%) 
and liver metastasis (11.9%) were the most prevalent symptoms/co-morbidities in 
the 12-month post-index period; 42.2 % had hospitalization admissions and 35.0% 
had ED visits, and the mean annual number of physician office visits was 25.5. The 
total monthly medical cost increased from $2,787 in the pre-index period to $3,788 
in the post-index period. ConClusions: Economic burden of untreated individuals 
with NETs is not negligible in the health care system. Future research should assess 
reasons for non-treatment, the impact of non-treatment on quality of life, and the 
benefit to cover this population with medical unmet need.
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objeCtives: Two vaccines protecting against human papillomavirus (HPV) infec-
tions are available in Bangladesh for the protection of girls against cervical can-
cer. These vaccines require cold chain storage and transportation to ensure their 
maximal efficacy. This storage may represent a large investment depending on 
the cold chain volume (CCV) needed. The objective of this study was to estimate 
and compare the total CCV needed for the vaccination of a single cohort of girls in 
Bangladesh accounting for the difference in packaging for each vaccine. Methods: 
The total CCV was estimated by multiplying the annual size of the cohort to be 
vaccinated by the CCV per dose and the number of doses needed per vaccination 
schedule. Additionally, a buffer factor of 10% as well as a wastage factor (5% for a 
1-dose-vial and 10% for a 2-dose-vial) were also accounted for as an assumption. 
Two vaccines were considered: the AS04-adjuvanted HPV-16/18 vaccine (AS04v) 
(2-dose-vial) and the HPV-6/11/16/18 vaccine (6/11/16/18V) (1-dose-vial). Dosing 
scheme (2-dose(2D) for AS04v, 3-dose(3D) for 6/11/16/18V) was according to label 
in Bangladesh. Alternative 2D for 6/11/16/18V recommended by World Health 
Organization (WHO) was also used. Their respective CCV per dose were obtained 
from the WHO Immunization Standards. A cohort size of N= 1,591,697 of girls aged 
10 eligible for vaccination was calculated from HPVCenter data. Results: CCV for 
AS04v is 4.8cm³ per dose for a 2-dose-vial and for 6/11/16/18V 15 cm³ per dose for 
a 1-dose-vial. To vaccinate a single cohort of girls the AS04v (2D) would require a 
total annual CCV capacity of 18.5m³ vs. 82.7m³ for the 6/11/16/18V (3D) or 55.2m³ for 
6/11/16/18V (2D). ConClusions: The AS04v was estimated to require between 3.0 
and 4.5 less total CCV than the 6/11/16/18V per vaccinated cohort in Bangladesh. 
This could translate into substantial logistical costs saved in Bangladesh.
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objeCtives: Saudi Arabia is the most important pharmaceutical market in the 
Middle East with a quickly growing population, a GDP in the top 30 globally and a 
high willingness to pay for pharmaceuticals. This represents a very attractive market 
for biopharmaceutical companies and their respective therapies as the market is 
expected to reach nearly $5B USD by 2016. This research aimed to understand the 
evolving and complex reimbursement landscape in the country and develop strate-
gies to capitalize on opportunities in the region, specifically focusing on high cost 
oncology therapeutics. Methods: The research was conducted through in-depth 
interviews with payers and clinicians across each government sector/ministry in 
Riyadh, Jeddah and Dammam. Results: The health care system in Saudi Arabia 
is decentralised and reimbursement decisions are made by individual government 
sectors (ministries). Recent reforms in the health care system have attempted to 
create a movement towards being more cost conscious. The majority of pharmacy 
departments at specialist hospitals in the leading 3 cities conduct pharmacoeconomic 
reviews, with varying rigor, although the impact is much less than that of the clinical 
review. Currently, the Saudi FDA is the regulatory authority in the country for pricing 
and reimbursement; however there is an increasing trend where pharmaceutical 
companies are taking alternate avenues to get high cost products reimbursed in the 
country. We identified and qualified opportunities and threats for high cost oncology 
products in the region. ConClusions: Despite the complexity of the market, invest-
ing in this large and developing marketplace will surely raise the profile of the country 
and provide great opportunity for the manufacturer. Given the large population and 
high willingness to pay, Saudi Arabia represents a very attractive market that should 
not be overlooked by pharmaceutical companies. Navigating the labyrinth strategi-
cally will ultimately help manufacturers achieve formidable success in the market.
PCN242
eviDeNCe For regioNal variaTioN iN The aPPraiSal oF iNDiviDUal 
CaNCer DrUgS FUND reqUeSTS
Macaulay R.
HERON Commercialization, London, UK
objeCtives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
cancer patients to gain access to therapies that are not routinely available on the 
NHS. A national CDF cohort policy lists drugs to be funded for patients who meet 
